Trial Profile
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 23 Jan 2024 Planned End Date changed from 21 Dec 2023 to 31 Dec 2025.
- 23 Jan 2024 Planned primary completion date changed from 21 Dec 2023 to 31 Dec 2025.
- 17 Feb 2023 Planned End Date changed from 21 Dec 2022 to 21 Dec 2023.